Company / Depreciation & Amortization
Vaxcyte, Inc. Depreciation & Amortization History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Depreciation & Amortization
$16.4M
FY2025
5-year range
$1.8M / $16.4M
FY2021-FY2025
Trend
+134.1%
vs FY2024
Sector context
#50 of 168
Health Care
What the data says
At $16M, Vaxcyte, Inc.'s depreciation & amortization ranks #119 of 168 in the Health Care sector. Depreciation & Amortization has increased for 7 consecutive years, from $1M in FY2018 to $16M in FY2025.
Based on SEC 10-K filings.
$16M in FY2025 with a 5-year CAGR of +63.5%.
Increased from $3M to $16M over the past 2 years.
Health Care sector context is included.
Depreciation & Amortization over time
Growth rates
- 3-Year CAGR
- +79.5%
- 5-Year CAGR
- +63.5%
- 10-Year CAGR
- -
Sector benchmark
#119 of 168 in Health CareTop 70% of 168This company $16.4M Sector average $212.9M
▼
-92.3% below sector average
Key checks
Key Insights
- Vaxcyte, Inc.'s depreciation & amortization has grown for 7 consecutive years.
- 5-year CAGR of +63.5%, indicating consistent growth.
- In FY2025, depreciation & amortization increased 134.1% year-over-year.
- Ranks #50 out of 168 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 2.94 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Depreciation & AmortizationValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $16.4M | +134.1% |
| FY2024 | $7.0M | +121.9% |
| FY2023 | $3.2M | +11.4% |
| FY2022 | $2.8M | +57.4% |
| FY2021 | $1.8M | +28.1% |
| FY2020 | $1.4M | +14.0% |
| FY2019 | $1.2M | +18.8% |
| FY2018 | $1.0M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026